Report overview
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
This report contains market size and forecasts of Viral Vectors Gene Therapy in Global, including the following market information:
Global Viral Vectors Gene Therapy Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Viral Vectors Gene Therapy market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Retro Viral Vectors Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Viral Vectors Gene Therapy include Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics, Anges, Bluebird Bio, Jazz Pharmaceuticals and Dynavax Technologies, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Viral Vectors Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Viral Vectors Gene Therapy Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Viral Vectors Gene Therapy Market Segment Percentages, by Type, 2022 (%)
Retro Viral Vectors
Adeno-associated Virus Vectors
Other Viral Vectors
Global Viral Vectors Gene Therapy Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Viral Vectors Gene Therapy Market Segment Percentages, by Application, 2022 (%)
In Vivo
Ex Vivo
Global Viral Vectors Gene Therapy Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Viral Vectors Gene Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Viral Vectors Gene Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Viral Vectors Gene Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences
